Heidelberg Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Heidelberg Pharma şirketinin toplam hissedar öz sermayesi €35.8M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €65.8M ve €30.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€36.57m
Eşitlik	€35.82m
Toplam yükümlülükler	€29.95m
Toplam varlıklar	€65.77m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HPHA 'nin kısa vadeli varlıkları ( €52.4M ) kısa vadeli yükümlülüklerini ( €8.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: HPHA şirketinin kısa vadeli varlıkları ( €52.4M ) uzun vadeli yükümlülüklerini ( €21.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HPHA borçsuzdur.

Borcun Azaltılması: HPHA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HPHA şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: HPHA un, serbest nakit akışı her yıl % 19.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Heidelberg Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023)

Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 14% to €8.85

Heidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024

New minor risk - Share price stability

Price target decreased by 13% to €7.75

Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Second quarter 2023 earnings released

Heidelberg Pharma Ag Announces Executive Changes

Price target decreased by 19% to €8.87

Price target decreased by 19% to €8.87

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to €10.30

Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)

Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Price target increased to €10.78

Heidelberg Pharma AG announced that it expects to receive €36 million in funding

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US

CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the company

Heidelberg Pharma AG Provides Financial Guidance for 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)

Heidelberg Pharma to Present Its Proprietary ATAC Technology

First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)

Heidelberg Pharma AG Reaffirms Earnings Guidance for 2021

Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2021

Heidelberg Pharma AG Heidelberg Pharma Expands Management Team

New 90-day high: €8.28

Heidelberg Pharma AG and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Price target raised to €6.52

Heidelberg Pharma AG Announces FDA Allows the Company to Start A Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Heidelberg Pharma AG, Annual General Meeting, May 18, 2021

New 90-day high: €5.32

New 90-day high: €4.88

Heidelberg Pharma AG Announces Several Presentations of Research Results on ATAC Technology At the ASH Annual Meeting 2020

New 90-day low: €3.55

Heidelberg Pharma AG Updates Financial Guidance for the Year 2020

Third quarter earnings released

New 90-day low: €3.83

New 90-day low - €3.90

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin